ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 90

Genetic Variants in IL-6, IL-10, C5-TRAF1 and FCRL3 and Progression of Joint Damage in Rheumatoid Arthritis; A Study on Six Cohorts

H.W. van Steenbergen1, L. Rodriguez-Rodriguez2, E. Berglin3, A. Zhernakova4, R. Knevel1, J. Ivorra-Cortes5, T.W.J. Huizinga1, B. Fernández-Gutiérrez6, P.K. Gregersen7, S. Rantapää-Dahlqvist8 and A.H.M. van der Helm-van Mil1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 3Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, 4Genetics, University Medical Center Groningen, Groningen, Netherlands, 5Rheumatology, University Hospital la Fe, Valencia, Spain, 6Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 7The Feinstein Institute for Medical Research, Manhasset, NY, 8Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: genetics, Joint destruction and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics, Genomics and Proteomics I

Session Type: Abstract Submissions (ACR)

Background/Purpose Understanding the mechanisms underlying the inter-individual differences in radiographic progression is relevant and heritability studies have shown that genetic factors explain part of these inter-individual differences. Indeed, some genetic variants have been identified and replicated in independent studies or found significant in meta-analyses. The literature on genetic variants and joint destruction in RA was systematically reviewed recently; for genetic variants in IL-6, IL-10, C5-TRAF1, and FCRL3 the existing literature was indefinite on whether these variants are associated with joint destruction. We aimed to clarify associations of genetic variants in IL-6, IL-10, C5-TRAF1 and FCRL3 with radiographic progression by evaluating six independent cohorts.

Methods In total 5,895 sets of radiographs of 2,493 RA patients included in the Leiden EAC, Umeå, HCSC-RAC, Wichita, NDB and NARAC cohorts were studied in relation to rs1800795 (IL-6), rs1800896 (IL-10), rs2900180 (C5-TRAF1) and rs7528684 (FCLR3). Associations with radiographic progression rates were tested per cohort using an additive model, adjusting for age, gender and treatment when appropriate. The results on yearly radiographic progression rates were combined in inverse variance weighted meta-analyses. Analyses were done on the total RA population and after stratification for anti-citrullinated peptide antibodies (ACPA).  Furthermore, the associated region C5-TRAF1 was fine-mapped.

Results No associations were found for rs1800795 (IL-6), rs1800896 (IL-10) and rs7528684 (FCLR3) in the total RA population and after stratification for ACPA. Also the directionality of the effects was diverse. Although for rs2900180 in C5-TRAF1 no significance was obtained in the total population or in ACPA-positive RA, an association was observed in ACPA-negative RA (p value meta-analysis 5.85×10-7). In all data sets with ACPA-negative RA, the minor allele was associated with more radiographic progression. Fine-mapping revealed a region of 66 Kb that was associated with radiographic progression; the lowest p-value was for rs7021880 in TRAF1. The p-value for rs7021880 in meta-analysis was 6.35×10-8. Previous studies indicate that the region of rs7021880 was associated with RNA expression of TRAF1 in monocytes after lipopolysaccharide stimulation.

Conclusion In contrast to initial reports, variants in IL-6, IL-10 and FCLR3 were not associated with radiographic progression in the present large meta-analyses. Although an association between rs2900180 in C5-TRAF1 and joint destruction was initially identified in the total RA population, we here replicated an association of rs2900180 in C5-TRAF1 and linked variants in a 66 Kb region with radiographic progression in ACPA-negative RA.


Disclosure:

H. W. van Steenbergen,
None;

L. Rodriguez-Rodriguez,
None;

E. Berglin,
None;

A. Zhernakova,
None;

R. Knevel,
None;

J. Ivorra-Cortes,
None;

T. W. J. Huizinga,
None;

B. Fernández-Gutiérrez,
None;

P. K. Gregersen,
None;

S. Rantapää-Dahlqvist,
None;

A. H. M. van der Helm-van Mil,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-variants-in-il-6-il-10-c5-traf1-and-fcrl3-and-progression-of-joint-damage-in-rheumatoid-arthritis-a-study-on-six-cohorts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology